Phosphodiesterase (PDE) Inhibitors Market - Industry Size, Share, Growth & Forecast 2030 | UnivDatos
“New Small-Molecule Drugs: The Hope of Revolutionizing Chronic Retinal Diseases Treatment" Chronic Retinal Diseases affect nearly 350 million people worldwide, primarily including cases of age-related macular degeneration (AMD), diabetic retinopathy (DR), and retinitis pigmentosa (RP). These retinal disorders have gained traction in recent years owing to increased usage of digital platforms, genetic mutations, and rising cases of obesity, diabetes, and high blood pressure. As per reports from the National Institute of Health in July 2020, retinal disorders had a prevalence of 5.35% to 21.02% at age 40 years and above. They can also initiate from environmental and genetic perturbations of tissue as well as cellular homeostasis. Innovation with phosphodiesterase (PDE) inhibitors : A major challenge associated with this arena is to preserve the retinal structure and to stop the progression of disease at earlier stages. The introduction of the concept of inhibition of cyc...